Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
- Status
- TERMINATED
- Phase
- NA
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- N/A
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- Status
- TERMINATED
- Phase
- PHASE1
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Blood Samples to Identify Biomarkers of Busulfan
- Status
- TERMINATED
- Phase
- N/A
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)
- Status
- COMPLETED
- Phase
- N/A
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- N/A
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy
- Status
- TERMINATED
- Phase
- NA
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
- Status
- COMPLETED
- Phase
- PHASE2